Novo Nordisk's GLP-1 Drug Competition Intensifies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Should l Buy ISRG?
Source: NASDAQ.COM
- Intensified Market Competition: Novo Nordisk's oral version of the GLP-1 drug Ozempic has reignited competition with Eli Lilly in the weight loss drug market, highlighting the fierce rivalry and innovation potential within the pharmaceutical industry.
- Surgeon Robot Demand Growth: By the end of 2025, Intuitive Surgical had 11,106 da Vinci surgical robots in operation, a 12% increase, with surgeries performed rising 18%, indicating a sustained demand for robotic surgery in the healthcare sector.
- Relative Valuation Appeal: Although Intuitive Surgical's price-to-earnings ratio stands at 61, which is below the five-year average of 71, it presents a relatively attractive investment opportunity for growth-focused investors looking for value.
- AI Technology Application Prospects: Intuitive Surgical is incorporating artificial intelligence into its surgical robots, with the potential for these robots to perform surgeries in the future, enhancing its competitive edge and technological leadership in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ISRG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ISRG
Wall Street analysts forecast ISRG stock price to rise
20 Analyst Rating
16 Buy
4 Hold
0 Sell
Strong Buy
Current: 496.250
Low
575.00
Averages
637.32
High
740.00
Current: 496.250
Low
575.00
Averages
637.32
High
740.00
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intuitive Surgical's Growth Potential in Robotics Market
- Strong Market Demand: Intuitive Surgical has installed over 11,100 da Vinci surgical robots globally, indicating high demand for its products and services, which is expected to continue driving revenue growth, particularly as 75% of its income comes from services and accessory sales, creating a stable income stream.
- Changing Competitive Landscape: While Intuitive Surgical is a pioneer in surgical robotics, the healthcare industry is highly competitive, with Medtronic's Hugo system recently receiving FDA approval and performing its first surgeries in the U.S., potentially threatening Intuitive Surgical's market share and prompting faster innovation.
- Significant Valuation Discrepancy: Intuitive Surgical's price-to-earnings ratio stands at 64, while Medtronic's is at 27; although Medtronic's diversified business may limit growth potential, strong performance from the Hugo system could attract investor attention and elevate its valuation.
- Dividend Appeal: Medtronic offers a dividend yield of approximately 2.9%, appealing to income-seeking investors, while Intuitive Surgical does not provide dividends, which may affect its attractiveness among certain investors, especially in the current market environment.
See More
5 Stocks Soaring as AI Boosts Robotics
AI's Impact on Robotics: The integration of artificial intelligence (AI) is fundamentally transforming robotics, enhancing their capabilities and accelerating adoption across various industries, including healthcare, logistics, and consumer applications.
Tesla's Innovations: Tesla is recognized not only for electric vehicles but also for its advancements in autonomous robotics, with projects like Optimus, which aims to create adaptable robots for various tasks, potentially revolutionizing labor-intensive industries.
NVIDIA's Role: NVIDIA serves as a crucial provider of AI infrastructure for robotics, offering powerful computing resources that enable advanced perception, decision-making, and real-time processing necessary for modern robotic systems.
Deere & Company's Automation Shift: Deere has transitioned from traditional equipment manufacturing to a technology-driven automation company, focusing on smart farming solutions that utilize AI for improved efficiency and sustainability in agriculture.
See More
Intuitive Surgical's Robotics Business Sees Strong Growth
- Strong Market Demand: Intuitive Surgical has installed over 11,100 da Vinci surgical robots globally, indicating high demand for its products, with approximately 75% of revenue derived from services and accessory sales, creating a stable recurring income stream for the company.
- New Product Launch: The company has just launched its Hugo surgical robot in the U.S., marking further expansion into the American market; despite facing competition, this new product has the potential to drive future revenue growth for the company.
- Valuation Comparison: Intuitive Surgical's price-to-earnings ratio stands at 64, significantly higher than competitor Medtronic's 27, which, while reflecting market confidence in growth potential, may also lead investors to be more cautious in their selections.
- Investor Sentiment: Despite Intuitive Surgical's leadership in the surgical robotics space, analysts suggest that investors should also consider Medtronic's Hugo system, which could gain FDA approval and boost the company's valuation, especially given Medtronic's dividend yield of approximately 2.9%.
See More
Intuitive Surgical's Growth Potential in Robotics Market
- Strong Market Demand: Intuitive Surgical has installed over 11,100 da Vinci surgical robots globally, indicating high demand for its products and services, with approximately 75% of revenue derived from ongoing services and accessory sales, creating a stable income stream that enhances financial stability.
- Changing Competitive Landscape: With Medtronic's Hugo surgical robot receiving FDA approval and performing its first surgeries in the U.S., competition intensifies; although Medtronic's P/E ratio is 27, lower than Intuitive Surgical's 64, its diversified business may limit growth potential.
- Emerging Investment Opportunity: As a pioneer in surgical robotics, Intuitive Surgical's high valuation reflects market confidence in its future growth, prompting investors to consider entry now to benefit from potential growth waves ahead.
- Dividend Appeal: Medtronic offers an attractive dividend yield of around 2.9%, appealing to income-seeking investors, while Intuitive Surgical does not provide dividends, giving Medtronic an edge in attracting dividend-focused investors.
See More
Competitive Analysis of Surgical Robotics Market
- Market Leadership: Intuitive Surgical's da Vinci surgical systems reached 11,106 installations by the end of 2025, reflecting a 12% year-over-year increase, with surgeries performed rising 18%, indicating strong demand in the medical community, although only 25% of revenue comes from new robot sales, with the remainder from parts and services, creating a stable income stream.
- Competitive Opportunity: While Intuitive Surgical has a high P/E ratio of 64, Medtronic's more attractive valuation at 26, coupled with its rapidly developing surgical robot Hugo, which received FDA approval for U.S. use in late 2025, suggests significant growth potential ahead.
- Diversification Advantage: As one of the world's largest medical device companies, Medtronic's diversified product line supports its expansion into surgical robotics, positioning it to share in the rapidly growing market alongside Intuitive Surgical.
- Dividend Appeal: Medtronic offers a 2.9% dividend yield and is nearing Dividend King status, suggesting that as its Hugo system gains market share over the next decade, investors could see stock price appreciation, providing both income and growth opportunities.
See More
Rockport Wealth LLC Establishes New Position in AIRR ETF
- New Position Established: On February 5, 2026, Rockport Wealth LLC disclosed a new position in the First Trust RBA American Industrial Renaissance ETF (AIRR) by purchasing 97,377 shares valued at $9.57 million, reflecting confidence in the industrial sector's recovery.
- Portfolio Diversification: AIRR now represents 1.9% of Rockport Wealth LLC's total reportable AUM, complementing major holdings like FDL ($71.4 million) and ISRG ($32.3 million), thereby enhancing the portfolio's growth potential and safety.
- Strong ETF Performance: As of February 5, 2026, AIRR shares were priced at $113.49, up 42.6% over the past year, outperforming the S&P 500 by 29 percentage points, indicating significant success in its investment strategy focused on small and mid-cap companies.
- Optimistic Industry Outlook: With the U.S. ISM Manufacturing PMI rising above 50, signaling economic expansion, the industrial sector is expected to benefit in 2026, and Rockport Wealth's investment in AIRR is viewed as a classic sector rotation bet that could yield higher returns.
See More
Intuitive Surgical's Growth Potential in Robotics Market
- Strong Market Demand: Intuitive Surgical has installed over 11,100 da Vinci surgical robots globally, indicating high demand for its products and services, which is expected to continue driving revenue growth, particularly as 75% of its income comes from services and accessory sales, creating a stable income stream.
- Changing Competitive Landscape: While Intuitive Surgical is a pioneer in surgical robotics, the healthcare industry is highly competitive, with Medtronic's Hugo system recently receiving FDA approval and performing its first surgeries in the U.S., potentially threatening Intuitive Surgical's market share and prompting faster innovation.
- Significant Valuation Discrepancy: Intuitive Surgical's price-to-earnings ratio stands at 64, while Medtronic's is at 27; although Medtronic's diversified business may limit growth potential, strong performance from the Hugo system could attract investor attention and elevate its valuation.
- Dividend Appeal: Medtronic offers a dividend yield of approximately 2.9%, appealing to income-seeking investors, while Intuitive Surgical does not provide dividends, which may affect its attractiveness among certain investors, especially in the current market environment.
See More
5 Stocks Soaring as AI Boosts Robotics
AI's Impact on Robotics: The integration of artificial intelligence (AI) is fundamentally transforming robotics, enhancing their capabilities and accelerating adoption across various industries, including healthcare, logistics, and consumer applications.
Tesla's Innovations: Tesla is recognized not only for electric vehicles but also for its advancements in autonomous robotics, with projects like Optimus, which aims to create adaptable robots for various tasks, potentially revolutionizing labor-intensive industries.
NVIDIA's Role: NVIDIA serves as a crucial provider of AI infrastructure for robotics, offering powerful computing resources that enable advanced perception, decision-making, and real-time processing necessary for modern robotic systems.
Deere & Company's Automation Shift: Deere has transitioned from traditional equipment manufacturing to a technology-driven automation company, focusing on smart farming solutions that utilize AI for improved efficiency and sustainability in agriculture.
See More
Intuitive Surgical's Robotics Business Sees Strong Growth
- Strong Market Demand: Intuitive Surgical has installed over 11,100 da Vinci surgical robots globally, indicating high demand for its products, with approximately 75% of revenue derived from services and accessory sales, creating a stable recurring income stream for the company.
- New Product Launch: The company has just launched its Hugo surgical robot in the U.S., marking further expansion into the American market; despite facing competition, this new product has the potential to drive future revenue growth for the company.
- Valuation Comparison: Intuitive Surgical's price-to-earnings ratio stands at 64, significantly higher than competitor Medtronic's 27, which, while reflecting market confidence in growth potential, may also lead investors to be more cautious in their selections.
- Investor Sentiment: Despite Intuitive Surgical's leadership in the surgical robotics space, analysts suggest that investors should also consider Medtronic's Hugo system, which could gain FDA approval and boost the company's valuation, especially given Medtronic's dividend yield of approximately 2.9%.
See More
Intuitive Surgical's Growth Potential in Robotics Market
- Strong Market Demand: Intuitive Surgical has installed over 11,100 da Vinci surgical robots globally, indicating high demand for its products and services, with approximately 75% of revenue derived from ongoing services and accessory sales, creating a stable income stream that enhances financial stability.
- Changing Competitive Landscape: With Medtronic's Hugo surgical robot receiving FDA approval and performing its first surgeries in the U.S., competition intensifies; although Medtronic's P/E ratio is 27, lower than Intuitive Surgical's 64, its diversified business may limit growth potential.
- Emerging Investment Opportunity: As a pioneer in surgical robotics, Intuitive Surgical's high valuation reflects market confidence in its future growth, prompting investors to consider entry now to benefit from potential growth waves ahead.
- Dividend Appeal: Medtronic offers an attractive dividend yield of around 2.9%, appealing to income-seeking investors, while Intuitive Surgical does not provide dividends, giving Medtronic an edge in attracting dividend-focused investors.
See More
Competitive Analysis of Surgical Robotics Market
- Market Leadership: Intuitive Surgical's da Vinci surgical systems reached 11,106 installations by the end of 2025, reflecting a 12% year-over-year increase, with surgeries performed rising 18%, indicating strong demand in the medical community, although only 25% of revenue comes from new robot sales, with the remainder from parts and services, creating a stable income stream.
- Competitive Opportunity: While Intuitive Surgical has a high P/E ratio of 64, Medtronic's more attractive valuation at 26, coupled with its rapidly developing surgical robot Hugo, which received FDA approval for U.S. use in late 2025, suggests significant growth potential ahead.
- Diversification Advantage: As one of the world's largest medical device companies, Medtronic's diversified product line supports its expansion into surgical robotics, positioning it to share in the rapidly growing market alongside Intuitive Surgical.
- Dividend Appeal: Medtronic offers a 2.9% dividend yield and is nearing Dividend King status, suggesting that as its Hugo system gains market share over the next decade, investors could see stock price appreciation, providing both income and growth opportunities.
See More
Rockport Wealth LLC Establishes New Position in AIRR ETF
- New Position Established: On February 5, 2026, Rockport Wealth LLC disclosed a new position in the First Trust RBA American Industrial Renaissance ETF (AIRR) by purchasing 97,377 shares valued at $9.57 million, reflecting confidence in the industrial sector's recovery.
- Portfolio Diversification: AIRR now represents 1.9% of Rockport Wealth LLC's total reportable AUM, complementing major holdings like FDL ($71.4 million) and ISRG ($32.3 million), thereby enhancing the portfolio's growth potential and safety.
- Strong ETF Performance: As of February 5, 2026, AIRR shares were priced at $113.49, up 42.6% over the past year, outperforming the S&P 500 by 29 percentage points, indicating significant success in its investment strategy focused on small and mid-cap companies.
- Optimistic Industry Outlook: With the U.S. ISM Manufacturing PMI rising above 50, signaling economic expansion, the industrial sector is expected to benefit in 2026, and Rockport Wealth's investment in AIRR is viewed as a classic sector rotation bet that could yield higher returns.
See More
